Tagged with Research

Pharma Nanomedicine is expected to become the third pillar of drug development following pharmaceuticals and biologics. The CEO of Dutch contract research and manufacturing organization ChemConnection explains how the company helps customers bring nanomedicine drug delivery systems and APIs from discovery to clinic, fast. Could you please introduce ChemConnection to our…

pharma Escalate Sciences is a Puerto Rican specialized science-based consulting firm focused on R&D, tech transfer, process design & improvement, analytical development and characterization. The company also serves different aspects of the life-sciences industry including project management, validation, qualification, statistical analysis, facility start-up, regulatory & compliance, reformulation and testing services. Its…

pharma Leonardo Vingiani, Director of Assobiotec, discusses how the country’s biotech industry has evolved since 2009, what areas still need improving and the enormous progress which has been made in unlocking the sector’s potential in Italy. Leonardo, to start off, what are some of the major milestones which the industry, and…

pharma Francisco García was appointed as the executive director for the Puerto Rico Manufacturers Association (PRMA) in August 2015. He stresses the importance of developing Puerto Rico’s entrepreneurial talent and startup clusters as his main initiatives. As you have recently taken over as executive director of PRMA, could you outline the…

pharma The founder and managing director of LT Clinical Research, one of the first wholly black-owned South African CRO, reveals how South Africa is a very conducive environment for CROs, with a diverse patient population, a well-established regulatory framework and a currency that compares well to other African currencies; why the…

pharma The General Manager of Boehringer Ingelheim South Africa talks about changes that are required to the healthcare system, with far more government/private partnerships, helping to unlock the country´s potential, why South Africa acts as a springboard for many companies looking to develop their footprint in the region, making it the…

pharma Thomas Würdinger, winner of the 2014 Galenus prize, discusses his research team’s efforts to developing new treatment options and protocols for brain cancers, and the need for greater attention and investment in brain cancer treatment development, an area he identifies as the greatest unmet medical need in the field of…

pharma  David Lenihan, CEO of Ponce Health Sciences University (PHSU), and Kenira Thompson, president of the Ponce Research Institute, highlight the institution’s pioneering efforts in creating cultural competency for medical graduates and increasing investments in clinical research from the US for large-scale trials. What are your perceptions of Puerto Rico’s research…

pharma Agustín Rullán, Dean of the College of Engineering at UPR Mayagüez, discusses the institution’s latest developments in engineering courses and their applicability in a practical industrial setting for students to jumpstart their professional careers. As a leading engineering college with 4,300 undergraduates and 400 graduates, the College plays a very…

Pharma The owner of Altis Biologics, Nick Duneas, illustrates the significance of the company’s flagship product, the Altis Osteogenic Bone Matrix (OBM) and how the company plans to commercialize the injectable bone graft substitute on a domestic and international scale moving forward. He also highlights how the Innovation Prize for Africa has…

Pharma The CEO of Diaxonhit Group, a fully integrated French leader in in vitro diagnostics, discusses the company’s strategic focus on specialty vitro diagnostics, his perspective on the challenge of consolidation that the diagnostics industry faces, as well as his cautiously optimistic assessment of  French competitiveness in the pharmaceutical and life…

Pharma The Netherlands Cancer Institute (NKI) has been at the international forefront of cancer research and treatment for more than 100 years. The director of research discusses the fields and collaborations the institute is currently focusing on and why funding to (blue-sky) research should be seen as an investment. What were…